case_images: PMC6136466_01
case_images: PMC6136466_02
case_images: PMC6136466_03
case_images: Magnetic resonance imaging of patient's brain obtained before and after initiation of ibrutinib. (a) Subependymal enhancement in December 2014 (T1 postcontrast). (b) Periventricular hyperintensity in December 2014 (FLAIR). (c) Leptomeningeal enhancement in December 2014 (postcontrast). (d) Left optic sheath enhancement in January 2015 (postcontrast). (e) Subependymal enhancement resolved in March 2015 (T1 postcontrast). (f) Periventricular hyperintensity resolved in March 2015 (FLAIR). (g) Leptomeningeal enhancement resolved in March 2015 (postcontrast). (h) Left optic sheath enhancement decreased in March 2015 (postcontrast).
case_images: CRIHEM2018-8573105.001.jpg
case_images: PMC6136466_04_CRIHEM2018-8573105.001.jpg
case_images: fig1
case_images: MRI brain was repeated in March 2015, showing interval improvement with decreased signal abnormality adjoining the atrium of the lateral ventricle and only mild persistent left optic nerve sheath enhancement (Figure 1).
case_images: PMC6136466_04
case_images: Magnetic resonance imaging of patient's brain obtained before and after initiation of ibrutinib. (a) Subependymal enhancement in December 2014 (T1 postcontrast). (b) Periventricular hyperintensity in December 2014 (FLAIR). (c) Leptomeningeal enhancement in December 2014 (postcontrast). (d) Left optic sheath enhancement in January 2015 (postcontrast). (e) Subependymal enhancement resolved in March 2015 (T1 postcontrast). (f) Periventricular hyperintensity resolved in March 2015 (FLAIR). (g) Leptomeningeal enhancement resolved in March 2015 (postcontrast). (h) Left optic sheath enhancement decreased in March 2015 (postcontrast).
case_images: CRIHEM2018-8573105.001.jpg
case_images: PMC6136466_04_CRIHEM2018-8573105.001.jpg
case_images: fig1
case_images: MRI brain was repeated in March 2015, showing interval improvement with decreased signal abnormality adjoining the atrium of the lateral ventricle and only mild persistent left optic nerve sheath enhancement (Figure 1).